Go Pro
NYSE:BHC

Bausch Health Cos (BHC) Stock Price, News & Analysis

Bausch Health Cos logo
$6.90 +0.01 (+0.09%)
Closing price 07/31/2026 03:59 PM Eastern
Extended Trading
$6.92 +0.02 (+0.33%)
As of 07/31/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Bausch Health Cos Stock (NYSE:BHC)

Advanced

Key Stats

Today's Range
$5.98
$6.92
50-Day Range
$4.43
$6.90
52-Week Range
$4.33
$8.69
Volume
22.80 million shs
Average Volume
3.74 million shs
Market Capitalization
$2.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Reduce

Company Overview

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices. Bausch + Lomb is also active in aesthetics with products used in ophthalmic surgery and ocular cosmetics. In its Diversified Brands segment, the company delivers a portfolio of dermatology treatments for both prescription and consumer use, gastrointestinal therapies for irritable bowel syndrome and ulcerative colitis, as well as neurology products targeting migraine prevention and treatment.

Tracing its roots back to a Canadian pharmaceutical firm founded in 1959, the company underwent significant expansion after acquiring Bausch + Lomb in 2013 under the Valeant name. In May 2018, the enterprise rebranded as Bausch Health Companies Inc to reflect a renewed focus on core pharmaceutical and eye health operations. Today, it maintains manufacturing sites and research facilities across North America, Europe, Latin America and Asia-Pacific, serving patients and healthcare professionals in more than 100 countries.

Under the leadership of President and Chief Executive Officer Joseph C. Cacciatore, Bausch Health has pursued portfolio optimization, debt reduction and a disciplined approach to research and development. The company continues to invest in its pipeline of specialty medicines and eye health solutions, while seeking to enhance access to care through strategic partnerships and targeted licensing agreements around the world.

AI Generated. May Contain Errors.

Bausch Health Cos Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

BHC MarketRank™: 

Bausch Health Cos scored higher than 43% of companies evaluated by MarketBeat, and ranked 618th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bausch Health Cos has received a consensus rating of Reduce. The company's average rating score is 1.71, and is based on no strong buy ratings, no buy ratings, 5 hold ratings, and 2 sell ratings.

  • Upside Potential

    Bausch Health Cos has a consensus price target of $8.00, representing about 16.0% upside from its current price of $6.90.

  • Amount of Analyst Coverage

    Bausch Health Cos has only been the subject of 3 research reports in the past 90 days.

  • Read more about Bausch Health Cos' stock forecast and price target.
  • Earnings Growth

    Earnings for Bausch Health Cos are expected to decrease by -10.62% in the coming year, from $4.05 to $3.62 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bausch Health Cos is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bausch Health Cos is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bausch Health Cos has a P/B Ratio of 6.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.48% of the float of Bausch Health Cos has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch Health Cos has a short interest ratio ("days to cover") of 3.73, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch Health Cos has recently increased by 0.52%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Bausch Health Cos does not currently pay a dividend.

  • Dividend Growth

    Bausch Health Cos does not have a long track record of dividend growth.

  • News Sentiment

    Bausch Health Cos has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 29 news articles for Bausch Health Cos this week, compared to 4 articles on an average week.
  • Search Interest

    11 people have searched for BHC on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Bausch Health Cos to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bausch Health Cos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $132,796.00 in company stock.

  • Percentage Held by Insiders

    20.67% of the stock of Bausch Health Cos is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    78.65% of the stock of Bausch Health Cos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bausch Health Cos' insider trading history.
Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Cos and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BHC Stock News Headlines

Bausch Health Cos (NYSE:BHC) Trading 8.2% Higher - What's Next?
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
Wall Street Zen Upgrades Bausch Health Cos (NYSE:BHC) to Strong-Buy
Zacks Research Expects Weaker Earnings for Bausch Health Cos
See More Headlines

BHC Stock Analysis - Frequently Asked Questions

Bausch Health Cos' stock was trading at $6.95 at the beginning of 2026. Since then, BHC shares have decreased by 0.8% and is now trading at $6.8960.

Bausch Health Cos Inc. (NYSE:BHC) posted its quarterly earnings data on Wednesday, July, 29th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.30. The business earned $2.83 billion during the quarter, compared to the consensus estimate of $2.59 billion. Bausch Health Cos had a negative net margin of 10.12% and a negative trailing twelve-month return on equity of 561.95%.
Read the conference call transcript
.

Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bausch Health Cos investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Tesla (TSLA), Bristol Myers Squibb (BMY) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
7/29/2026
Today
8/03/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:BHC
CIK
885590
Employees
20,300
Year Founded
1959

Price Target and Rating

High Price Target
$9.00
Low Price Target
$7.00
Potential Upside/Downside
+16.0%
Consensus Rating
Reduce
Rating Score (0-4)
1.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
1.70
P/E Growth
N/A
Net Income
$157 million
Net Margins
-10.12%
Pretax Margin
-6.74%
Return on Equity
-561.95%
Return on Assets
6.31%

Debt

Debt-to-Equity Ratio
54.68
Current Ratio
1.44
Quick Ratio
1.08

Sales & Book Value

Annual Sales
$10.85 billion
Price / Sales
0.24
Cash Flow
$7.26 per share
Price / Cash Flow
0.95
Book Value
$1.02 per share
Price / Book
6.76

Miscellaneous

Outstanding Shares
374,032,000
Free Float
296,720,000
Market Cap
$2.58 billion
Optionable
Optionable
Beta
0.42

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NYSE:BHC) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners